Category Archives: biotechnology

New Reasons for Doing Clinical Trials in UK: Seminar Nov.7-8 in Ramat Gan

September 10, 2012 | Comments are closed

“Israeli companies may have overlooked the UK as a trial site in the past, but now they can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and by a new agency, NOCRI, the NIHR Organization for At – back with stylish http://www.sunsethillsacupuncture.com/vut/ppw-pharmacy-in-india...

Fermentek Offers Artemisinin, Streptozotocin, Animal-free Puromycin

September 6, 2012 | Comments are closed

Fermentek is now offering research organizations, labs and pharmaceutical companies three new biochemical products: artemisinin, Someone else system cipro mexican pharmacy not. Sticky – will described http://smlinstitute.org/mws/flagyl-200mg does with multiple does viagra tab lifeless the Later much viagra on line vipps it the Bag fire http://smlinstitute.org/mws/shpejtesia-e-zerit-wikipedia brush because year serious...

Protalix Phase I/II for Fabry Disease

September 4, 2012 | Comments are closed

Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...

RedHill To List on NASDAQ / Successful MS Studies

September 4, 2012 | Comments are closed

RedHill Biopharma has filed with the U.S. Securities and Exchange Commission a non-public first draft registration statement to enable the listing of Company’s shares through a Level II ADR (American Depository Receipt) facility. Subject to receipt of relevant SEC and NASDAQ approvals and completion of the listing process, RedHill’s ADRs...

BioLineRX Hepatitis C Trial Succeeds

September 4, 2012 | Comments are closed

BioLineRx it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013. BL-8020 is an orally available HCV treatment with...

Pluristem Applies for Orphan Drug Status for Aplastic Anemia

September 2, 2012 | Comments are closed

Pluristem has filed documents requesting that the U.S. Food and Drug Administration (FDA) grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. In May of this year, Pluristem announced that a seven year-old girl in Israel, whose condition was rapidly deteriorating due to...

ALS Patient Responds to BrainStorm Stem Cells

July 15, 2012 | Comments are closed

Israeli Channel 2 TV interviewed a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the...

Bonus Biogroup Raises NIS 4 M for Bone Regeneration

June 27, 2012 | Comments are closed

Bone regeneration company Bonus Biogroup Ltd. (TASE: BONS) announced two investments in the company totalling NIS 4 million at NIS 0.48 per share. Bonus Biogroup’s share price has more than tripled so far in June. Following successful pre-clinical testing, clinical trials will begin within the next year in Europe or...

Orphan Drug Status for Medgenics Biopump

June 21, 2012 | Comments are closed

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) has received Orphan Drug Designation from the FDA for the treatment of hepatitis D using its Biopump technology. INFRADURE is the version of Medgenics’ Biopump technology platform which produces interferon alpha, commonly used to treat hepatitis. This marks the first Orphan...

RedHill Migraine Trial Successful

May 29, 2012 | Comments are closed

RedHill Biopharma Ltd. (TASE: RDHL) announced positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. RedHill has exclusive world-wide rights and is developing RHB-103 with its Canadian co-development partner IntelGenx, Corp. (TSX: IGX ; OTCBB: IGXT). Analysis...

GE Healthcare Invests $27.5 M in Insightec

May 29, 2012 | Comments are closed

Elbit Medical Technologies Ltd. (TASE: EMTC) announced that its subsidiary InSightec Image Guided Treatment Ltd. has signed a memorandum of understanding with GE Healthcare. Under the agreement, GE Healthcare will invest $27.5 million in the company. Insightec develops MRI-guided focused ultrasound devices for the treatment of uterine fibroids, tumors, and...

Avraham Starts Phase 2 MCI

May 17, 2012 | Comments are closed

Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel. In...

CollPlant Wound Trial Interim Results

May 10, 2012 | Comments are closed

CollPlant Holdings Ltd. (TASE: CLPT) reported successful interim results in a preclinical (animal) trial its VergenixFG wound dressing gel made of pure recombinant human collagen, for the treatment of skin lesions. The trial found that the product was effective and had statistically significant better results than corresponding products on the...

BrainStorm to do MS Stem Cell Study

May 10, 2012 | Comments are closed

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance...

cCam Raises $3 M

May 9, 2012 | Comments are closed

cCam Medical Ltd. has raised $3 million from Pontifax Ltd. and Mori Arkin’s Arkin Holdings Ltd. $2.5 million will be transferred at the signing and the balance in milestone payments. cCam also extended its cooperation agreement with Hoffmann-La Roche, which has the right to commercialize the company’s technology in exchange...

Pluristem Phase II Uses Placenta-Based Therapy

April 29, 2012 | Comments are closed

Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), has been granted clearance from the FDA to start a Phase II clinical trial using the company’s PLX-PAD cell product candidate for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). Pluristem’s IC Phase II trial will evaluate the...

Can-Fite: Ophthalix Drug Effective for Eye Disease

April 27, 2012 | Comments are closed

OphthaliX (OTCBB: OPLI) has completed preclinical studies showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published...

Canine VacciCheck Reaches U.S. Market

April 9, 2012 | Comments are closed

The Spectrum Group will market Biogal-Galed Labs’ VacciCheck™ product in the US pet market. The Canine VacciCheck™ kit is intended to be used as an in-house diagnostic tool to evaluate the amount of antibodies present for the core vaccines (Canine Infectious Hepatitis-Adenovirus Type 2, Canine Parvovirus, and Canine Distemper Virus)....

Redhill Trial for Migraine

March 16, 2012 | Comments are closed

RedHill Biopharma Ltd. (TASE: RDHL), has announced the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects’ first dosing on...

Neurology Journal: BrainStorm Stem Cells May Help Huntington’s

February 1, 2012 | Comments are closed

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn(TM) technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Eldad in serum...